2021. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s39. DOI:https://doi.org/10.25251/skin.5.supp.39.